History

MGF was characterized largely by Geoffrey Goldspink's group at UCL / the Royal Free in the late 1990s to 2000s. They described it as an alternative-splice product of the IGF-1 gene (IGF-1Ec in humans, IGF-1Eb in rodents) in which a 49-base-pair insert in exon 5 causes a reading-frame shift, producing a unique C-terminal E-domain peptide ("MGF E-peptide," about 24 amino acids in humans). The "mechano growth factor" name reflects the observation that mechanical loading or muscle damage transiently induces this isoform ahead of the sustained systemic IGF-1Ea isoform.

MGF (mechano growth factor) is a muscle-derived splice variant of insulin-like growth factor 1. It has a genuinely interesting biology and a plausible role in muscle repair, but it is sold as a research chemical (often as a PEGylated form, PEG-MGF) on the strength of mechanisms and animal work — not human results. The marketing runs well ahead of the evidence.

What it is

The IGF-1 gene can be spliced into more than one product. MGF is the splice variant known as IGF-1Ec in humans (IGF-1Eb in rodents). A 49-base-pair insert in exon 5 shifts the reading frame, which produces a distinct C-terminal E-domain peptide — the “MGF E-peptide,” roughly 24 amino acids in humans. This was worked out largely by Geoffrey Goldspink and colleagues.

The proposed biology is what makes it notable. Mechanical loading or muscle damage transiently induces MGF mRNA within hours — earlier than, and distinct from, the sustained systemic IGF-1Ea isoform. The proposed role is a local autocrine/paracrine repair signal: MGF activates quiescent satellite cells (muscle stem cells), driving their proliferation and delaying differentiation, after which IGF-1Ea drives differentiation, fusion, and protein synthesis. The E-peptide appears to have some activity that does not depend on the mature IGF-1 receptor. This is a coherent, well-cited model — not a proven clinical effect.

PEG-MGF is a research-grade synthetic version of the E-peptide with a polyethylene-glycol (PEGylation) modification meant to extend its very short half-life. It is a non-pharmaceutical “research chemical” construct, not a characterized drug product.

The claims

Vendors and forums promote MGF and PEG-MGF for building muscle, faster recovery from training, satellite-cell activation, fat loss, and various “anti-aging” or metabolic benefits. These are typically presented as established effects of an injectable peptide. They are not established in humans.

What the evidence actually shows

The evidence base is mechanistic, cell-culture, and animal. There is essentially no human in-vivo drug evidence, and no completed human clinical trial of MGF or PEG-MGF as an administered drug — no real trial registration or published randomized controlled trial of exogenous MGF/PEG-MGF in living people was found. Treat any claim of clinical efficacy as unsupported.

What does exist:

Human cells in a dish (not a clinical trial): In primary human muscle cell cultures, the MGF E-peptide increased the proliferative lifespan of satellite cells (delaying senescence, in neonatal/young donors rather than aged ones) and increased their fusion potential. This is cell culture only — no human dosing (Kandalla et al., Mechanisms of Ageing and Development, 2011).
Mouse, brain: MGF overexpression increased neural stem-cell proliferation in aging mouse brain — a transgenic/animal result, and not about muscle or metabolism (Tang et al., Molecular Brain, 2017).
Mouse, ALS model: In SOD1(G93A) mice, MGF rescued motoneurons and improved muscle function (Riddoch-Contreras et al., Experimental Neurology, 2009). Animal only.
A negative result: In a piglet growth-plate/chondrocyte model, exogenously added MGF showed no proliferative effect — a useful reminder that effects are tissue-specific, not uniformly positive (Schlegel et al., PLoS One, 2013).

On fat loss and metabolic effects specifically, the evidence is thin to absent: no credible human (or strong animal) data establish MGF/PEG-MGF as a weight-loss or metabolic agent. Any positioning along those lines is speculative.

Legal and regulatory status

MGF and PEG-MGF are not approved anywhere, for any indication — no FDA, EMA, or other approval. They are research-grade / preclinical compounds, not licensed medicines. Material sold online is labeled “research use only,” which restricts lawful sale to bona fide laboratory research and is not a clearance for human use.

In sport, MGF is squarely banned. It is prohibited at all times — both in and out of competition — under the WADA Prohibited List, Section S2 (peptide hormones, growth factors, related substances and mimetics). The list explicitly names “mechano growth factors (MGFs)” alongside “insulin-like growth factor 1 (IGF-1) and its analogues” under the growth-factors subsection (S2.3), and these are non-specified substances, which carry the strictest sanctions. The 2026 list has been in force since January 1, 2026.

For contrast, not every popular compound sits on the Prohibited List: GLP-1 receptor agonists are not prohibited. They sit on WADA’s Monitoring Program (semaglutide since 2024, with tirzepatide added for 2026), not the Prohibited List. So MGF is an outright-banned growth factor, while GLP-1 agonists are merely monitored and permitted.

Safety

The honest answer is that the human safety profile is essentially uncharacterized. There is no human safety data from controlled trials, so phrases like “well tolerated” are not evidence-based for MGF.

The concerns that exist are theoretical and mechanistic, extrapolated from IGF-1 biology rather than proven for MGF: proliferative growth factors raise a plausible concern about promoting the growth of existing or occult tumors, and cardiac effects (myocardial hypertrophy) and tissue overgrowth are biologically plausible but not quantified for MGF. Separately, research-grade and PEG-MGF material sold outside the regulated supply chain carries unverified identity, purity, sterility, and endotoxin risk — a real-world hazard independent of the peptide’s intrinsic pharmacology. None of this is medical advice.

Bottom line

MGF has a genuinely interesting, well-characterized biology — a muscle-induced IGF-1 splice variant whose E-peptide plausibly acts as a local repair signal. But that is mechanism and animal work, not human outcomes. It is unapproved, has no completed human drug trials, has an unknown human safety profile, and is prohibited at all times in sport. The case for muscle building, fat loss, or recovery in people rests on extrapolation, not evidence.

Evidence grade: Animal only.

MGF (Mechano Growth Factor)